4Q16 Earnings Conference Call

February 27 2017

Presentation of Financial Information amp Forward Looking Statements

Historical financial and operating data in this presentation reflect the consolidated results of Integer for the periodsindicated

This presentation includes financial information prepared in accordance with accounting principles generally accepted inthe United States or GAAP as well as other financial measures referred to as non-GAAP The non-GAAP financialmeasures in this presentation which include Adjusted Net Income Adjusted Diluted EPS Earnings Before Interest TaxesDepreciation and Amortization (EBITDA) and Adjusted EBITDA should be considered in addition to but not assubstitutes for the information prepared in accordance with GAAP For reconciliations of these non-GAAP financialmeasures to the most comparable GAAP measures please refer to the appendix to this presentation and the earningsrelease associated with this quarterly period which can be found in the investor relations section of our corporate website(wwwintegernet)

Statements made in this presentation whether written or oral may be ldquoforward-looking statementsrdquo within the meaning ofSection 27A of the Securities Act of 1933 as amended and Section 21E of Securities Exchange Act of 1934 asamended and involve a number of risks and uncertainties These statements can be identified by terminology such asldquomayrdquo ldquowillrdquo ldquoshouldrdquo ldquocouldrdquo ldquoexpectsrdquo ldquointendsrdquo ldquoplansrdquo ldquoanticipatesrdquo ldquobelievesrdquo ldquoestimatesrdquo ldquopredictsrdquo ldquopotentialrdquo orldquocontinuerdquo or ldquovariationsrdquo or the negative of these terms or other comparable terminology These statements are based onthe companyrsquos current expectations and speak only as of February 27 2017 The Companyrsquos actual results could differmaterially from those stated or implied by such forward-looking statements The Company assumes no obligation toupdate forward-looking information including information in this presentation to reflect changed assumptions theoccurrence of unanticipated events or changes in future operating results financial conditions or prospects

Integer Confidential February 27 2017 Page 2

Agenda

bull Opening Comments

bull Financial Results

bull Product Line Review

bull Strategic Growth Initiatives

bull Closing Comments

bull Question amp Answer Period

Thomas J HookPresident amp CEO

Michael DinkinsExecutive Vice President amp Chief Financial Officer

Opening Comments

Quarterly Results Reflect Continued Progress

bull Business stabilization continues returning to a growth trajectory

bull New COO structure strategically aligns integrated capabilities more effectively

bull Building momentum and focused on winning new opportunities

bull Operational resultsbull Demonstrating fiscal disciplinebull Working capital initiatives driving results

bull Financial resultsbull 4Q16 revenue flat YoY and up $13M QoQbull Generating increased cash flow from operationsbull Accelerating debt repayment

bull Business well positioned for incremental growth in 2017

ldquoWe had solid

performance in the

fourth quarter and

are pleased with the

continued operational

and financial

stabilization of the

businessrdquo

Financial Results

4Q16 Financial Results(1)

($ in millions except per share amounts)

(1) 4Q16 Key Financial Results provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

(2) Includes $23M of inventory step-up amortization associated with the acquisition and integration of Lake Region Medical Excluding this amount gross margin for 4Q15 and FY15 would have been 279 for both periods

4Q15 3Q16 4Q16 FY15 FY16

Sales 360$ 347$ 360$ 1443$ 1386$

Gross Margin 215 283 258 264 272

Operating Expenses 89$ 61$ 62$ 302$ 270$

of Sales 247 176 172 209 195

GAAP Net Income (47)$ 11$ 8$ (39)$ 6$

Adjusted Net Income 28$ 26$ 27$ 98$ 84$

EBITDA (7)$ 59$ 56$ 161$ 203$

Adjusted EBITDA 79$ 75$ 71$ 304$ 280$

of Sales 219 216 196 211 202

GAAP Diluted EPS (154)$ 037$ 025$ (127)$ 019$

Adjusted Diluted EPS 087$ 083$ 087$ 311$ 268$

Cash Flow from Operations -- 38$ 34$ -- 106$

(2) (2)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

1Q152Q153Q154Q151Q162Q163Q164Q16138084144711468530000000000113261600000000001133651442189999999999914827314236799999999999CardiacNeuromodulation

1Q152Q153Q154Q151Q162Q163Q164Q1698866109157938490000000000041108995894999999999996916230000000000059578100000000000610492400000000001Advanced Surgical Orthopedics amp Portable Medical

1Q152Q153Q154Q151Q162Q163Q164Q161057731088398763000000000005105177000000000019132899999999999410431699999999999951910194199999999999Electrochem

1Q152Q153Q154Q151Q162Q163Q164Q16177116545000000000002119771321700000000000111672000000000001981900000000000088869999999999999211318Elimination of Interproduct line sales1Q152Q153Q154Q151Q162Q163Q164Q16-25659999999999998-23250000000000002-30219999999999998-2266-1488-15960000000000001-15469999999999999-096099999999999997

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Cash Flows

Cash Flow from Operations

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

Reqd Debt PaymentsFY1629Addl PaymentsFY1615

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

$138 $145 $147 $133 $134 $144 $148 $142

$99 $109 $94 $111 $96 $92 $96 $105

$106 $109

$99 $105 $91

$104 $95 $102

$18 $17

$12 $13 $12

$10 $9 $11

1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16

Continued Revenue Stabilization

$358

Non-Medical

Cardiac amp Neuro

Cardio amp Vascular

Adv Surgical Ortho ampPortable Medical

$377 $348 $360 $331 $348 $347

Quarterly Sales(1)

4Q16 SalesQoQ YoY YTD

38 (05) (40)

28 (14) (30)

7 (3) (6)

10 (5) (6)

(4) 7 1

Total Sales(2)

(1) Sales information provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

(2) Total sales includes the sum of sales for each of ITGRrsquos product lines as detailed on this slide and the elimination of Interproduct Line Sales for which amounts are not included on this slide

($ in millions) $360

$79

$65 $69 $75

$71

4Q15 1Q16 2Q16 3Q16 4Q16

Adjusted EBITDA

Adjusted EBITDA(1)

$0

($ in millions) bull Continued focus on improving business performance to generate cash

bull Ongoing pricing pressure reinforces focus on quality to drive volume increases and efficiency

bull Improve customer satisfaction

bull Reduce costs and expand share of wallet with customers

bull Cumulative synergies of $34Mbull Realized benefits offset by sales mix

pricing pressure salary increases and warranty inventory reserve charges

bull Excludes $121M of OOE and IP related litigation expenses in 4Q16(2)

(1) Adjusted EBITDA provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

(2) See APPENDIX for additional information regarding Other Operating Expenses (OOE) including historical data

22 of Sales 20 20 2022

DebtPayments

Strong Cash Flow Generation

bull Generating significant cash flow to meet current debt obligations and accelerate debt repayment

bull FY17 Cash Flow of $106M

bull Paid down $17M of debt in 4Q16 $46M YTD

bull Focused on reducing total leverage as quickly as possible

bull Total long-term debt of $18B as of YE 2016

bull No significant maturities until 2020

bull Mitigating exposure to interest rate volatility

bull Well within covenant compliance requirements(2)

bull Successfully amended credit agreement in 4Q16

($ in millions)

(1) Free Cash Flow defined as Cash from Operations less Capital Expenditures

(2) See the APPENDIX to this presentation for further discussion regarding financial covenant calculations

($ in millions)

$31 $41 $48 $88$240

$964

$360

2017 2018 2019 2020 2021 2022 2023

$11

$(8)

$21 $22

1Q16 2Q16 3Q16 4Q16

$30

$4

$38 $34

1Q16 2Q16 3Q16 4Q16

Cash Flow From Operations Free Cash Flow($ in millions)

FY16

Debt Repayment Schedule($ in millions)

$29

$17

$46

Accelerated RepaymentRequired Repayment

$361 $318 $317 $325 $332

4Q15 1Q16 2Q16 3Q16 4Q16

Inventory $252 $267 $276 $262 $225

Inventory Turns 4 4 4 4 5

Capital Expenditures $13 $19 $12 $17 $12

Working Capital

$0

($ in millions)

bull Targeting continued reduction in inventory levels through FY17

bull Enhanced Sales amp Operating Plan (SampOP) process showing improved results and more accurate forecasting

bull Rationalizing vendor partners to drive synergies and extend payment terms

bull On-going process improvement programs to reduce direct materials spend and indirect expenses

($ in millions)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

FY16Actual

FY17Outlook

Revenue $1386 $1390 - $1430

Adjusted Diluted EPS $268 $270 - $310

FY 2017 Outlook

bull Working Capital expected to improve $10M - $20M by YE2017

bull FY17 Adjusted Effective Tax Rate expected to be ~25

bull Cash Taxes expected to be ~$10M

bull Other Operating Expense expected to be in the range of $18M - $22M

bull Capital Expenditures expected to be in the range of $50M - $60M per year

bull Depreciation amp Amortization expected to be in the range of $95M - $100MStock

bull Stock-based compensation Expense expected to be ~$15M

Product Line Review

Advanced Surgical Orthopedics amp Portable Medical

Providing a wide range of technologies and solutions to the Advanced Surgical and Orthopedic markets

Implants Delivery Systems Reamers Laparoscopic Devices Arthroscopy Products

bull Revenue remains a solid contributor to total Company results down YOY driven by lower product launches during current quarter and accelerated demand in the prior year quarter

bull Shipped wireless prototype to first customer making good progress with additional customers

bull Steady operational performance driven by improvements in customer relationships

bull Multiple continuous improvement initiatives in place across our operations ndash early results are positive

bull Expect incremental revenue growth in 2017 driven by new product launches and acceleration in targeted areas

Cardio amp Vascular

Offering a full-range of products and services for catheter-based interventional vascular devices and a suite of supply chain solutions to support the

development and manufacturing of complex components sub-assemblies and finished devices

Steerable Sheaths Catheters amp Sheaths Guidewires Stylets amp Accessories

Introducers

bull 4Q16 Revenue increased 7 YoY ndash strong demand for precious metal machining components and OEM product lines

bull Operational performance backed by strong customer relationships enabling deeper penetration and increased customer opportunities

bull First commercial shipment late in 4Q16 of previously delayed key customer program will ramp throughout 2017

bull Positive outlook for 2017 ndash several new opportunities well-positioned in sales process

Cardiac amp Neuromodulation

Batteries Feedthroughs Enclosures Coated Electrodes

bull Continued positive quarterly momentum and sequential revenue improvement

bull Incremental growth opportunities within the market as OEM partners and customers seek value-added solutions as well as supply chain efficiencies

bull Leading position in the rapidly growing Neuromodulation market

bull Solid pipeline in various stages of development (generally a 2 to 5 year process)

bull Signed several new customer development agreements and manufacturing programs

Providing technology solutions for the active implantable medical device industry by partnering with customers to bring quality products to established and

emerging markets - from initial concept through to high volume manufacturing

Full System Solutions

Electrochem

Enhancing lives worldwide by providing superior power solutions that enable the success and advancement of our customersrsquo critical applications

Battery Cells

Battery Packs

Battery Chargers

bull Revenues continue to trend with Oil amp Gas marketbull Oil prices begun to stabilize in 4Q16

bull North American energy customer activity coming back online

bull Military and Environmental customer volumes remain steady

bull Engaging with customers across all market segments ndash actively pursuing new customer and market opportunities

bull Growing market share within the space new opportunities driven by long history of operational and quality performance

bull Advancing competitive position through multi-year supply agreements

Strategic Growth Initiatives

Key Strategic Focus Areas

bull Laser focused on achieving strategic objectivesbull Invest to drive growth with customers across full spectrum of

product and systems capabilities

bull Deliver shareholder returns through growth in profitability and cash generation to drive accelerate debt repayment

bull Optimize the commitment and contribution of our Associates by cultivating an ethical values-driven culture

bull Current integration efforts remain on trackbull Formal activities complete mid-2017

bull Expect to achieve total synergies of $60M by YE2018

bull Creating an optimized manufacturing footprintbull Continuous improvement and productivity initiatives

bull Direct material and indirect expense savings

bull Centers of excellence around the world

bull No further plans to close or consolidate locations at this time

ldquoOur vision is to

enhance the lives of

patients worldwide

by being our

customersrsquo partner of

choice for innovative

technologies and

servicesrdquo

Closing Comments

Well-Positioned for Future Growth

Operating amp Manufacturing

Scalability

Strong Customer Relationships

Business Optimization

Driving Strong Cash Generation

Innovation Pipeline to Enable

Customer Success

Engineered Medical

Components

Engineered Medical Sub Assemblies

Differentiated Medical

Components amp Subassemblies

Transfer Devices

Co-Developed

Devices

IntegerDesigned Devices

Fully Branded Solutions

Medical Device

Systems

Product Solutions(More IP Focused)

Technical Solutions(Traditional CMO)

80 20

Broad Product Continuum

Question amp Answer Period

APPENDIX

Other Operating Expenses

(1) Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

1116 123016 1116 123016 NOTES

2014 Investments in Capacity and Capabilities $52 $33 $230 $172

Portable Medical and Vascular product line transfers

Orthopedic Facilities Optimization $00 $01 $14 $07

Lake Region Medical Consolidation and Optimization $20 $12 $20 $86

Acquisition and Integration Costs $281 $52 $335 $283 Lake Region Medical and CCC Medical Devices

Asset Dispositions Severance and Other $17 $19 $66 $69 Nuvectra spin-off

Comparable Basis Adjustments net(1) $35 $00 $182 ($11)

TOTAL OOE $405 $117 $847 $606

Three Months Ended Twelve Months Ended

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q16298580000000000013895999999999999938045000000000002Free Cash Flow

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

Debt ndash Financial Covenant Calculations

(1) Financial Covenant ratios adjust in future reporting periods Details are available in ITGRrsquos publicly filed credit agreements

(2) R12 = Rolling 12 months

(3) R12 Cash Interest Expense excludes debt related amortization amounts included in Interest Expense

(4) Future Synergies and Cost Savings

bull At the end of each fiscal quarter Integer can add the planned impact of synergies and cost savings initiatives connected to the Lake Region acquisition for the next twelve months

bull These are calculated on a pro forma basis assuming they had been in effect at the beginning of the test period

bull Synergies may include the incremental Adjusted EBITDA impact of revenue synergies These would be new revenue initiatives that are specifically enabled by the merger

bull Synergies are limited to a maximum of $35 million The allowable adjustment changes over time beginning in 2017

Financial Covenant Calculations(1)(2)

Leverage Ratio (lt 625 4Q16)Leverage Ratio = Net Debt R12 Bank EBITDA

Interest Coverage Ratio (gt 250 4Q16)Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

Net DebtNet DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

Bank EBITDAR12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Non-GAAP ReconciliationNet Income and Diluted EPS Reconciliation ndash QTD

See the Footnotes to this table on Slide 28 of this presentation

Three Months EndedDecember 30 2016 January 1 2016

(in thousands except per share amounts) Pre-TaxNet

Income

PerDilutedShare Pre-Tax

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Amortization of intangibles(a) 9411 6646 021 7488 5277 018Inventory step-up amortization (COS)(a) mdash mdash mdash 22986 15605 052IP related litigation (SGampA)(a)(b) 349 227 001 1131 735 002Consolidation and optimization expenses (OOE)(a)(c) 4686 3884 012 7191 5736 019Acquisition and integration expenses (OOE)(a)(d) 5173 3406 011 28083 20924 069Asset dispositions severance and other (OOE)(a)(e) 1874 1301 004 1741 1499 005Lake Region Medical transaction costs (interest expense)(a)(f) mdash mdash mdash 4675 3039 010Loss on cost and equity method investments net(a) 1765 1147 004 1769 1150 004Tax adjustments(g) mdash 2630 008 mdash (1200) (004)Taxes(a) (627) mdash mdash (9745) mdash mdash

As reported adjusted (Non-GAAP)(h) 27174 087 27858 092Comparable basis adjustments net(i) mdash mdash (71) (005)

Comparable basis adjusted (Non-GAAP)(h) $ 27174 $ 087 $ 27787 $ 087

As reported adjusted diluted weighted average shares(j) 31254 30125Comparable basis adjusted diluted weighted average shares(j)(k) 31254 31805

Non-GAAP ReconciliationNet Income and Diluted EPS Reconciliation ndash YTD

Year EndedDecember 30 2016 January 1 2016

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

Amortization of intangibles(a) 37862 26771 086 17496 12273 045Inventory step-up amortization (COS)(a) mdash mdash mdash 22986 15605 057IP related litigation (SGampA)(a)(b) 3040 1976 006 4417 2871 011Consolidation and optimization expenses (OOE)(a)(c) 26490 21582 069 26393 21158 077Acquisition and integration expenses (OOE)(a)(d) 28316 18554 059 33449 25885 095Asset dispositions severance and other (OOE)(a)(e) 6931 5760 018 6622 5099 019Lake Region Medical transaction costs (interest expense)(a)(f) mdash mdash mdash 9463 6151 023(Gain) loss on cost and equity method investments net(a) 833 541 002 (3350) (2177) (008)Tax adjustments(g) mdash (154) mdash mdash mdash mdashTaxes(a) (23666) mdash mdash (22505) mdash mdash

As reported adjusted (Non-GAAP)(h) 80991 259 79271 290Comparable basis adjustments net(i) 2624 008 18833 021

Non-GAAP ReconciliationsFootnotes to ldquoNet Income and Diluted EPS Reconciliationrdquo

a) The difference between pre-tax and net income (loss) amounts is the estimated tax impact related to the respective adjustment Net income amounts are computed using a 35 US Mexico Germany and France statutory tax rate a 0 Swiss tax rate a 20 Netherlands statutory tax rate a 25 Uruguay statutory tax rate and a 125 Ireland statutory tax rate Expenses that are not deductible for tax purposes (ie permanent tax differences) are added back at 100

b) In 2013 we filed suit against AVX Corporation alleging they were infringing our intellectual property Given the complexity and significant costs incurred pursuing this litigation we are excluding these litigation expenses from adjusted amounts This matter proceeded to trial during the first quarter of 2016 and a federal jury awarded the Company $375 million in damages To date no gains have been recognized in connection with this litigation

c) During 2016 and 2015 we incurred costs primarily related to the transfer of our Beaverton OR portable medical and Plymouth MN vascular manufacturing operations to Tijuana Mexico Additionally with the acquisition of Lake Region Medical 2016 costs also include expenses incurred in connection with the closure of Lake Region Medicalrsquos Arvada CO site and the consolidation of its two Galway Ireland sites which was initiated by Lake Region Medical in 2014

d) During 2016 and 2015 we incurred acquisition and integration costs related to the acquisition of Lake Region Medical which was acquired in October 2015 During 2015 we incurred costs related to the integration of CCC Medical Devices which was acquired in August 2014

e) Costs primarily include legal and professional fees incurred in connection with the spin-off of Nuvectra which was completed in March 2016 as well as various asset disposition charges

f) During the third and fourth quarters of 2015 we recorded transaction costs (ie debt commitment fees interest rate swap termination costs debt extinguishment charges) in connection with our acquisition of Lake Region Medical

g) Tax adjustments for the 2016 periods include a discrete tax benefit related to certain transaction costs of the Lake Region Medical acquisition and the spin-off of Nuvectra recorded in the third quarter and a tax charge recorded in the fourth quarter in connection with the enactment of regulations under sect987 of the Internal Revenue Code which resulted in an adjustment to our deferred tax assets For the 2015 fourth quarter tax adjustments consist of the 2015 Federal RampD tax credit which was enacted during that period and was permanently reinstated

h) The per share data in this table has been rounded to the nearest $001 and therefore may not sum to the totali) Comparable basis adjustments for 2016 represent the exclusion of the results of Nuvectra prior to its spin-off on March 14 2016 Nuvectrarsquos 2016 revenue tax

benefit adjusted net loss and adjusted diluted EPS prior to its spin-off was $12 million $18 million $26 million and a loss of $008 per share respectively Comparable basis adjustments for the 2015 periods represent the exclusion of the Nuvectra results and the inclusion of the former Lake Region Medical results prior to its acquisition on October 27 2015 Our historical pro forma information presentation which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable basis amounts to as reported amounts

j) The as reported and comparable basis adjusted diluted weighted average shares for full year 2016 includes 249000 potentially dilutive shares not included in the computation of diluted weighted average common shares for GAAP diluted EPS purposes because their effect would have been anti-dilutive given the Companyrsquos net loss in the first and second quarters Fourth quarter and full year 2015 as reported and comparable basis adjusted diluted weighted average shares include 947000 and 941000 additional shares respectively related to outstanding equity awards that were not dilutive for GAAP EPS purposes

k) Comparable basis diluted weighted average shares for the 2015 periods include the pro forma impact of shares issued in conjunction with the acquisition of Lake Region Medical as if the acquisition occurred at the beginning of the period No adjustment is necessary for the 2016 periods as shares issued for the acquisition are included in the Companyrsquos outstanding shares in accordance with GAAP

Non-GAAP ReconciliationsAdjusted EBITDA Reconciliation

a) Comparable basis adjustments for 2016 represent the exclusion of the results of Nuvectra prior to its spin-off on March 14 2016 Nuvectrarsquos 2016 GAAP net loss EBITDA and adjusted EBITDA prior to its spin-off was $34 million $49 million and $37 million respectively Comparable basis adjustments for the 2015 periods represent the exclusion of the Nuvectra results for the entire period and the inclusion of the former Lake Region Medical results prior to its acquisition on October 27 2015 Our historical pro forma information presentation which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable basis amounts to as reported amounts

Three Months Ended Year Ended

(dollars in thousands)December 30

2016January 1

2016December 30

2016January 1

2016Net income (loss) as reported $ 7933 $ (24907) $ 5961 $ (7594)

Interest expense 27875 25362 111270 33513Benefit for income taxes (3390) (12554) (4776) (8106)Depreciation 13699 10203 52662 27136Amortization 9411 7488 37862 17496

EBITDA 55528 5592 202979 62445

Inventory step-up amortization mdash 22986 mdash 22986IP related litigation 349 1131 3040 4417Stock-based compensation 1160 288 6933 9287Consolidation and optimization expenses 4686 7191 26490 26393Acquisition and integration expenses 5173 28083 28316 33449Asset dispositions severance and other 1874 1741 6931 6622Noncash loss on cost and equity method investments 1765 1993 1495 275

As reported adjusted EBITDA (Non-GAAP) 70535 69005 276184 165874Comparable basis adjustments(a) mdash 9930 3665 138323Comparable basis adjusted EBITDA (Non-GAAP) $ 70535 $ 78935 $ 279849 $ 304197

As reported adjusted EBITDA as a of sales 196 217 199 207Comparable basis adjusted EBITDA as a of sales 196 219 202 211

Non-GAAP Reconciliations2017 Full-Year Outlook

Except as described below further reconciliations by line item to the closest corresponding GAAP financial measures for Adjusted Basis Earnings per Diluted Share included in our ldquoBusiness Outlookrdquo above are not available without unreasonable efforts on a forward-looking basis due to the high variability complexity and visibility of the charges excluded from this non-GAAP financial measure

Adjusted EPS for 2017 is expected to consist of GAAP Net Income and EPS excluding items such as intangible amortization IP related litigation costs and consolidation acquisition integration and asset dispositionwrite-down charges totaling approximately $72 million The after-tax impact of these items is estimated to be approximately $50 million or approximately $160 per diluted share

High Low High Low

Revenue $1430 $1390 $1430 $1390

Earnings per Diluted Share $150 $110 $310 $270

GAAP Adjusted Comparable Basis

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Amy WakehamVP Investor Relations

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1360


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	4Q15		1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		$11		($8)		$21		$22


Days Sales Outstanding		0		50		50		50		52


Inventory		$252		$267		$276		$262		$225


Inventory Turns		4		4		4		4		5


Capital Expenditures		$13		$19		$12		$17		$12


Days Payables Outstanding		0		32		36		32		27


Sales		359634		331058		348382		346567		359591

COGS		282377		240244		252351		248658		266700

Accounts Recievables			183563		192121		191409		204626

Net Inventory		252166		267380		276279		262232		225151

Accounts Payable			83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Page 2: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

Historical financial and operating data in this presentation reflect the consolidated results of Integer for the periodsindicated

This presentation includes financial information prepared in accordance with accounting principles generally accepted inthe United States or GAAP as well as other financial measures referred to as non-GAAP The non-GAAP financialmeasures in this presentation which include Adjusted Net Income Adjusted Diluted EPS Earnings Before Interest TaxesDepreciation and Amortization (EBITDA) and Adjusted EBITDA should be considered in addition to but not assubstitutes for the information prepared in accordance with GAAP For reconciliations of these non-GAAP financialmeasures to the most comparable GAAP measures please refer to the appendix to this presentation and the earningsrelease associated with this quarterly period which can be found in the investor relations section of our corporate website(wwwintegernet)

Statements made in this presentation whether written or oral may be ldquoforward-looking statementsrdquo within the meaning ofSection 27A of the Securities Act of 1933 as amended and Section 21E of Securities Exchange Act of 1934 asamended and involve a number of risks and uncertainties These statements can be identified by terminology such asldquomayrdquo ldquowillrdquo ldquoshouldrdquo ldquocouldrdquo ldquoexpectsrdquo ldquointendsrdquo ldquoplansrdquo ldquoanticipatesrdquo ldquobelievesrdquo ldquoestimatesrdquo ldquopredictsrdquo ldquopotentialrdquo orldquocontinuerdquo or ldquovariationsrdquo or the negative of these terms or other comparable terminology These statements are based onthe companyrsquos current expectations and speak only as of February 27 2017 The Companyrsquos actual results could differmaterially from those stated or implied by such forward-looking statements The Company assumes no obligation toupdate forward-looking information including information in this presentation to reflect changed assumptions theoccurrence of unanticipated events or changes in future operating results financial conditions or prospects

Agenda

Opening Comments

ldquoWe had solid

performance in the

fourth quarter and

and financial

businessrdquo

Financial Results

4Q15 3Q16 4Q16 FY15 FY16

Sales 360$ 347$ 360$ 1443$ 1386$

Gross Margin 215 283 258 264 272

of Sales 247 176 172 209 195

GAAP Net Income (47)$ 11$ 8$ (39)$ 6$

EBITDA (7)$ 59$ 56$ 161$ 203$

Adjusted EBITDA 79$ 75$ 71$ 304$ 280$

of Sales 219 216 196 211 202

GAAP Diluted EPS (154)$ 037$ 025$ (127)$ 019$

(2) (2)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

$138 $145 $147 $133 $134 $144 $148 $142

$99 $109 $94 $111 $96 $92 $96 $105

$106 $109

$99 $105 $91

$104 $95 $102

$18 $17

$12 $13 $12

$10 $9 $11

1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16

$358

Non-Medical

Cardiac amp Neuro

Cardio amp Vascular

$377 $348 $360 $331 $348 $347

Quarterly Sales(1)

38 (05) (40)

28 (14) (30)

7 (3) (6)

10 (5) (6)

(4) 7 1

Total Sales(2)

$79

$65 $69 $75

$71

4Q15 1Q16 2Q16 3Q16 4Q16

Adjusted EBITDA

Adjusted EBITDA(1)

$0

22 of Sales 20 20 2022

DebtPayments

($ in millions)

$31 $41 $48 $88$240

$964

$360

2017 2018 2019 2020 2021 2022 2023

$11

$(8)

$21 $22

1Q16 2Q16 3Q16 4Q16

$30

$4

$38 $34

1Q16 2Q16 3Q16 4Q16

FY16

$29

$17

$46

$361 $318 $317 $325 $332

4Q15 1Q16 2Q16 3Q16 4Q16

Inventory $252 $267 $276 $262 $225

Working Capital

$0

($ in millions)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

FY16Actual

FY17Outlook

Revenue $1386 $1390 - $1430

FY 2017 Outlook

Product Line Review

Cardio amp Vascular

Introducers

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1360


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	4Q15		1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		$11		($8)		$21		$22


Days Sales Outstanding		0		50		50		50		52


Inventory		$252		$267		$276		$262		$225


Inventory Turns		4		4		4		4		5


Capital Expenditures		$13		$19		$12		$17		$12


Days Payables Outstanding		0		32		36		32		27


Sales		359634		331058		348382		346567		359591

COGS		282377		240244		252351		248658		266700

Accounts Recievables			183563		192121		191409		204626

Net Inventory		252166		267380		276279		262232		225151

Accounts Payable			83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Page 3: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

Agenda

Opening Comments

ldquoWe had solid

performance in the

fourth quarter and

and financial

businessrdquo

Financial Results

4Q15 3Q16 4Q16 FY15 FY16

Sales 360$ 347$ 360$ 1443$ 1386$

Gross Margin 215 283 258 264 272

of Sales 247 176 172 209 195

GAAP Net Income (47)$ 11$ 8$ (39)$ 6$

EBITDA (7)$ 59$ 56$ 161$ 203$

Adjusted EBITDA 79$ 75$ 71$ 304$ 280$

of Sales 219 216 196 211 202

GAAP Diluted EPS (154)$ 037$ 025$ (127)$ 019$

(2) (2)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

$138 $145 $147 $133 $134 $144 $148 $142

$99 $109 $94 $111 $96 $92 $96 $105

$106 $109

$99 $105 $91

$104 $95 $102

$18 $17

$12 $13 $12

$10 $9 $11

1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16

$358

Non-Medical

Cardiac amp Neuro

Cardio amp Vascular

$377 $348 $360 $331 $348 $347

Quarterly Sales(1)

38 (05) (40)

28 (14) (30)

7 (3) (6)

10 (5) (6)

(4) 7 1

Total Sales(2)

$79

$65 $69 $75

$71

4Q15 1Q16 2Q16 3Q16 4Q16

Adjusted EBITDA

Adjusted EBITDA(1)

$0

22 of Sales 20 20 2022

DebtPayments

($ in millions)

$31 $41 $48 $88$240

$964

$360

2017 2018 2019 2020 2021 2022 2023

$11

$(8)

$21 $22

1Q16 2Q16 3Q16 4Q16

$30

$4

$38 $34

1Q16 2Q16 3Q16 4Q16

FY16

$29

$17

$46

$361 $318 $317 $325 $332

4Q15 1Q16 2Q16 3Q16 4Q16

Inventory $252 $267 $276 $262 $225

Working Capital

$0

($ in millions)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

FY16Actual

FY17Outlook

Revenue $1386 $1390 - $1430

FY 2017 Outlook

Product Line Review

Cardio amp Vascular

Introducers

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1360


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	4Q15		1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		$11		($8)		$21		$22


Days Sales Outstanding		0		50		50		50		52


Inventory		$252		$267		$276		$262		$225


Inventory Turns		4		4		4		4		5


Capital Expenditures		$13		$19		$12		$17		$12


Days Payables Outstanding		0		32		36		32		27


Sales		359634		331058		348382		346567		359591

COGS		282377		240244		252351		248658		266700

Accounts Recievables			183563		192121		191409		204626

Net Inventory		252166		267380		276279		262232		225151

Accounts Payable			83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Page 4: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

Opening Comments

ldquoWe had solid

performance in the

fourth quarter and

and financial

businessrdquo

Financial Results

4Q15 3Q16 4Q16 FY15 FY16

Sales 360$ 347$ 360$ 1443$ 1386$

Gross Margin 215 283 258 264 272

of Sales 247 176 172 209 195

GAAP Net Income (47)$ 11$ 8$ (39)$ 6$

EBITDA (7)$ 59$ 56$ 161$ 203$

Adjusted EBITDA 79$ 75$ 71$ 304$ 280$

of Sales 219 216 196 211 202

GAAP Diluted EPS (154)$ 037$ 025$ (127)$ 019$

(2) (2)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

$138 $145 $147 $133 $134 $144 $148 $142

$99 $109 $94 $111 $96 $92 $96 $105

$106 $109

$99 $105 $91

$104 $95 $102

$18 $17

$12 $13 $12

$10 $9 $11

1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16

$358

Non-Medical

Cardiac amp Neuro

Cardio amp Vascular

$377 $348 $360 $331 $348 $347

Quarterly Sales(1)

38 (05) (40)

28 (14) (30)

7 (3) (6)

10 (5) (6)

(4) 7 1

Total Sales(2)

$79

$65 $69 $75

$71

4Q15 1Q16 2Q16 3Q16 4Q16

Adjusted EBITDA

Adjusted EBITDA(1)

$0

22 of Sales 20 20 2022

DebtPayments

($ in millions)

$31 $41 $48 $88$240

$964

$360

2017 2018 2019 2020 2021 2022 2023

$11

$(8)

$21 $22

1Q16 2Q16 3Q16 4Q16

$30

$4

$38 $34

1Q16 2Q16 3Q16 4Q16

FY16

$29

$17

$46

$361 $318 $317 $325 $332

4Q15 1Q16 2Q16 3Q16 4Q16

Inventory $252 $267 $276 $262 $225

Working Capital

$0

($ in millions)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

FY16Actual

FY17Outlook

Revenue $1386 $1390 - $1430

FY 2017 Outlook

Product Line Review

Cardio amp Vascular

Introducers

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1360


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	4Q15		1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		$11		($8)		$21		$22


Days Sales Outstanding		0		50		50		50		52


Inventory		$252		$267		$276		$262		$225


Inventory Turns		4		4		4		4		5


Capital Expenditures		$13		$19		$12		$17		$12


Days Payables Outstanding		0		32		36		32		27


Sales		359634		331058		348382		346567		359591

COGS		282377		240244		252351		248658		266700

Accounts Recievables			183563		192121		191409		204626

Net Inventory		252166		267380		276279		262232		225151

Accounts Payable			83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Page 5: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

ldquoWe had solid

performance in the

fourth quarter and

and financial

businessrdquo

Financial Results

4Q15 3Q16 4Q16 FY15 FY16

Sales 360$ 347$ 360$ 1443$ 1386$

Gross Margin 215 283 258 264 272

of Sales 247 176 172 209 195

GAAP Net Income (47)$ 11$ 8$ (39)$ 6$

EBITDA (7)$ 59$ 56$ 161$ 203$

Adjusted EBITDA 79$ 75$ 71$ 304$ 280$

of Sales 219 216 196 211 202

GAAP Diluted EPS (154)$ 037$ 025$ (127)$ 019$

(2) (2)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

$138 $145 $147 $133 $134 $144 $148 $142

$99 $109 $94 $111 $96 $92 $96 $105

$106 $109

$99 $105 $91

$104 $95 $102

$18 $17

$12 $13 $12

$10 $9 $11

1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16

$358

Non-Medical

Cardiac amp Neuro

Cardio amp Vascular

$377 $348 $360 $331 $348 $347

Quarterly Sales(1)

38 (05) (40)

28 (14) (30)

7 (3) (6)

10 (5) (6)

(4) 7 1

Total Sales(2)

$79

$65 $69 $75

$71

4Q15 1Q16 2Q16 3Q16 4Q16

Adjusted EBITDA

Adjusted EBITDA(1)

$0

22 of Sales 20 20 2022

DebtPayments

($ in millions)

$31 $41 $48 $88$240

$964

$360

2017 2018 2019 2020 2021 2022 2023

$11

$(8)

$21 $22

1Q16 2Q16 3Q16 4Q16

$30

$4

$38 $34

1Q16 2Q16 3Q16 4Q16

FY16

$29

$17

$46

$361 $318 $317 $325 $332

4Q15 1Q16 2Q16 3Q16 4Q16

Inventory $252 $267 $276 $262 $225

Working Capital

$0

($ in millions)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

FY16Actual

FY17Outlook

Revenue $1386 $1390 - $1430

FY 2017 Outlook

Product Line Review

Cardio amp Vascular

Introducers

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1360


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	4Q15		1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		$11		($8)		$21		$22


Days Sales Outstanding		0		50		50		50		52


Inventory		$252		$267		$276		$262		$225


Inventory Turns		4		4		4		4		5


Capital Expenditures		$13		$19		$12		$17		$12


Days Payables Outstanding		0		32		36		32		27


Sales		359634		331058		348382		346567		359591

COGS		282377		240244		252351		248658		266700

Accounts Recievables			183563		192121		191409		204626

Net Inventory		252166		267380		276279		262232		225151

Accounts Payable			83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Page 6: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

Financial Results

4Q15 3Q16 4Q16 FY15 FY16

Sales 360$ 347$ 360$ 1443$ 1386$

Gross Margin 215 283 258 264 272

of Sales 247 176 172 209 195

GAAP Net Income (47)$ 11$ 8$ (39)$ 6$

EBITDA (7)$ 59$ 56$ 161$ 203$

Adjusted EBITDA 79$ 75$ 71$ 304$ 280$

of Sales 219 216 196 211 202

GAAP Diluted EPS (154)$ 037$ 025$ (127)$ 019$

(2) (2)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

$138 $145 $147 $133 $134 $144 $148 $142

$99 $109 $94 $111 $96 $92 $96 $105

$106 $109

$99 $105 $91

$104 $95 $102

$18 $17

$12 $13 $12

$10 $9 $11

1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16

$358

Non-Medical

Cardiac amp Neuro

Cardio amp Vascular

$377 $348 $360 $331 $348 $347

Quarterly Sales(1)

38 (05) (40)

28 (14) (30)

7 (3) (6)

10 (5) (6)

(4) 7 1

Total Sales(2)

$79

$65 $69 $75

$71

4Q15 1Q16 2Q16 3Q16 4Q16

Adjusted EBITDA

Adjusted EBITDA(1)

$0

22 of Sales 20 20 2022

DebtPayments

($ in millions)

$31 $41 $48 $88$240

$964

$360

2017 2018 2019 2020 2021 2022 2023

$11

$(8)

$21 $22

1Q16 2Q16 3Q16 4Q16

$30

$4

$38 $34

1Q16 2Q16 3Q16 4Q16

FY16

$29

$17

$46

$361 $318 $317 $325 $332

4Q15 1Q16 2Q16 3Q16 4Q16

Inventory $252 $267 $276 $262 $225

Working Capital

$0

($ in millions)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

FY16Actual

FY17Outlook

Revenue $1386 $1390 - $1430

FY 2017 Outlook

Product Line Review

Cardio amp Vascular

Introducers

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1360


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	4Q15		1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		$11		($8)		$21		$22


Days Sales Outstanding		0		50		50		50		52


Inventory		$252		$267		$276		$262		$225


Inventory Turns		4		4		4		4		5


Capital Expenditures		$13		$19		$12		$17		$12


Days Payables Outstanding		0		32		36		32		27


Sales		359634		331058		348382		346567		359591

COGS		282377		240244		252351		248658		266700

Accounts Recievables			183563		192121		191409		204626

Net Inventory		252166		267380		276279		262232		225151

Accounts Payable			83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Page 7: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

4Q15 3Q16 4Q16 FY15 FY16

Sales 360$ 347$ 360$ 1443$ 1386$

Gross Margin 215 283 258 264 272

of Sales 247 176 172 209 195

GAAP Net Income (47)$ 11$ 8$ (39)$ 6$

EBITDA (7)$ 59$ 56$ 161$ 203$

Adjusted EBITDA 79$ 75$ 71$ 304$ 280$

of Sales 219 216 196 211 202

GAAP Diluted EPS (154)$ 037$ 025$ (127)$ 019$

(2) (2)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

$138 $145 $147 $133 $134 $144 $148 $142

$99 $109 $94 $111 $96 $92 $96 $105

$106 $109

$99 $105 $91

$104 $95 $102

$18 $17

$12 $13 $12

$10 $9 $11

1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16

$358

Non-Medical

Cardiac amp Neuro

Cardio amp Vascular

$377 $348 $360 $331 $348 $347

Quarterly Sales(1)

38 (05) (40)

28 (14) (30)

7 (3) (6)

10 (5) (6)

(4) 7 1

Total Sales(2)

$79

$65 $69 $75

$71

4Q15 1Q16 2Q16 3Q16 4Q16

Adjusted EBITDA

Adjusted EBITDA(1)

$0

22 of Sales 20 20 2022

DebtPayments

($ in millions)

$31 $41 $48 $88$240

$964

$360

2017 2018 2019 2020 2021 2022 2023

$11

$(8)

$21 $22

1Q16 2Q16 3Q16 4Q16

$30

$4

$38 $34

1Q16 2Q16 3Q16 4Q16

FY16

$29

$17

$46

$361 $318 $317 $325 $332

4Q15 1Q16 2Q16 3Q16 4Q16

Inventory $252 $267 $276 $262 $225

Working Capital

$0

($ in millions)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

FY16Actual

FY17Outlook

Revenue $1386 $1390 - $1430

FY 2017 Outlook

Product Line Review

Cardio amp Vascular

Introducers

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1360


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	4Q15		1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		$11		($8)		$21		$22


Days Sales Outstanding		0		50		50		50		52


Inventory		$252		$267		$276		$262		$225


Inventory Turns		4		4		4		4		5


Capital Expenditures		$13		$19		$12		$17		$12


Days Payables Outstanding		0		32		36		32		27


Sales		359634		331058		348382		346567		359591

COGS		282377		240244		252351		248658		266700

Accounts Recievables			183563		192121		191409		204626

Net Inventory		252166		267380		276279		262232		225151

Accounts Payable			83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Page 8: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

$138 $145 $147 $133 $134 $144 $148 $142

$99 $109 $94 $111 $96 $92 $96 $105

$106 $109

$99 $105 $91

$104 $95 $102

$18 $17

$12 $13 $12

$10 $9 $11

1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16

$358

Non-Medical

Cardiac amp Neuro

Cardio amp Vascular

$377 $348 $360 $331 $348 $347

Quarterly Sales(1)

38 (05) (40)

28 (14) (30)

7 (3) (6)

10 (5) (6)

(4) 7 1

Total Sales(2)

$79

$65 $69 $75

$71

4Q15 1Q16 2Q16 3Q16 4Q16

Adjusted EBITDA

Adjusted EBITDA(1)

$0

22 of Sales 20 20 2022

DebtPayments

($ in millions)

$31 $41 $48 $88$240

$964

$360

2017 2018 2019 2020 2021 2022 2023

$11

$(8)

$21 $22

1Q16 2Q16 3Q16 4Q16

$30

$4

$38 $34

1Q16 2Q16 3Q16 4Q16

FY16

$29

$17

$46

$361 $318 $317 $325 $332

4Q15 1Q16 2Q16 3Q16 4Q16

Inventory $252 $267 $276 $262 $225

Working Capital

$0

($ in millions)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

FY16Actual

FY17Outlook

Revenue $1386 $1390 - $1430

FY 2017 Outlook

Product Line Review

Cardio amp Vascular

Introducers

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1360


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	4Q15		1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		$11		($8)		$21		$22


Days Sales Outstanding		0		50		50		50		52


Inventory		$252		$267		$276		$262		$225


Inventory Turns		4		4		4		4		5


Capital Expenditures		$13		$19		$12		$17		$12


Days Payables Outstanding		0		32		36		32		27


Sales		359634		331058		348382		346567		359591

COGS		282377		240244		252351		248658		266700

Accounts Recievables			183563		192121		191409		204626

Net Inventory		252166		267380		276279		262232		225151

Accounts Payable			83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Page 9: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

$79

$65 $69 $75

$71

4Q15 1Q16 2Q16 3Q16 4Q16

Adjusted EBITDA

Adjusted EBITDA(1)

$0

22 of Sales 20 20 2022

DebtPayments

($ in millions)

$31 $41 $48 $88$240

$964

$360

2017 2018 2019 2020 2021 2022 2023

$11

$(8)

$21 $22

1Q16 2Q16 3Q16 4Q16

$30

$4

$38 $34

1Q16 2Q16 3Q16 4Q16

FY16

$29

$17

$46

$361 $318 $317 $325 $332

4Q15 1Q16 2Q16 3Q16 4Q16

Inventory $252 $267 $276 $262 $225

Working Capital

$0

($ in millions)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

FY16Actual

FY17Outlook

Revenue $1386 $1390 - $1430

FY 2017 Outlook

Product Line Review

Cardio amp Vascular

Introducers

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1360


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	4Q15		1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		$11		($8)		$21		$22


Days Sales Outstanding		0		50		50		50		52


Inventory		$252		$267		$276		$262		$225


Inventory Turns		4		4		4		4		5


Capital Expenditures		$13		$19		$12		$17		$12


Days Payables Outstanding		0		32		36		32		27


Sales		359634		331058		348382		346567		359591

COGS		282377		240244		252351		248658		266700

Accounts Recievables			183563		192121		191409		204626

Net Inventory		252166		267380		276279		262232		225151

Accounts Payable			83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

DebtPayments

($ in millions)

$31 $41 $48 $88$240

$964

$360

2017 2018 2019 2020 2021 2022 2023

$11

$(8)

$21 $22

1Q16 2Q16 3Q16 4Q16

$30

$4

$38 $34

1Q16 2Q16 3Q16 4Q16

FY16

$29

$17

$46

$361 $318 $317 $325 $332

4Q15 1Q16 2Q16 3Q16 4Q16

Inventory $252 $267 $276 $262 $225

Working Capital

$0

($ in millions)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

FY16Actual

FY17Outlook

Revenue $1386 $1390 - $1430

FY 2017 Outlook

Product Line Review

Cardio amp Vascular

Introducers

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1360


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	4Q15		1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		$11		($8)		$21		$22


Days Sales Outstanding		0		50		50		50		52


Inventory		$252		$267		$276		$262		$225


Inventory Turns		4		4		4		4		5


Capital Expenditures		$13		$19		$12		$17		$12


Days Payables Outstanding		0		32		36		32		27


Sales		359634		331058		348382		346567		359591

COGS		282377		240244		252351		248658		266700

Accounts Recievables			183563		192121		191409		204626

Net Inventory		252166		267380		276279		262232		225151

Accounts Payable			83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Page 11: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

$361 $318 $317 $325 $332

4Q15 1Q16 2Q16 3Q16 4Q16

Inventory $252 $267 $276 $262 $225

Working Capital

$0

($ in millions)

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

FY16Actual

FY17Outlook

Revenue $1386 $1390 - $1430

FY 2017 Outlook

Product Line Review

Cardio amp Vascular

Introducers

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1360


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	4Q15		1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		$11		($8)		$21		$22


Days Sales Outstanding		0		50		50		50		52


Inventory		$252		$267		$276		$262		$225


Inventory Turns		4		4		4		4		5


Capital Expenditures		$13		$19		$12		$17		$12


Days Payables Outstanding		0		32		36		32		27


Sales		359634		331058		348382		346567		359591

COGS		282377		240244		252351		248658		266700

Accounts Recievables			183563		192121		191409		204626

Net Inventory		252166		267380		276279		262232		225151

Accounts Payable			83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Page 12: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

FY16Actual

FY17Outlook

Revenue $1386 $1390 - $1430

FY 2017 Outlook

Product Line Review

Cardio amp Vascular

Introducers

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Page 13: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

Product Line Review

Cardio amp Vascular

Introducers

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Page 14: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

Cardio amp Vascular

Introducers

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Page 15: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

Cardio amp Vascular

Introducers

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Page 16: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Page 17: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

Electrochem

Battery Cells

Battery Packs

Battery Chargers

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Page 18: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Page 19: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

patients worldwide

by being our

technologies and

servicesrdquo

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Page 20: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

Closing Comments

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Page 21: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

Scalability

Customer Success

Engineered Medical

Components

Transfer Devices

Co-Developed

Devices

Medical Device

Systems

80 20

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Page 22: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Page 23: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

APPENDIX

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Page 24: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

1116 123016 1116 123016 NOTES

TOTAL OOE $405 $117 $847 $606

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Working Capital

4Q151Q162Q163Q164Q163607640000000000131789699999999993316610999999999993251580000000000233208699999999999

BS Metrics

Debt

Payment

2H1620172018201920202021202220231531414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q161109-7738000000000000421478999999999999

Guidance

Appendix --gt

Debt Covenants

OOE

Guidance-recon table

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 65 3Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 300 3Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27

Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16


	Sales		$ 348		$ 347		$ 360


	Gross Margin		282		283		258


	Operating Expenses		$ 74		$ 61		$ 62	-161	13


	of Sales		212		176		172


	GAAP Net Income		$ (5)		$ 11		$ 8


	Adjusted Net Income		$ 20		$ 26		$ 27


	EBITDA		$ 51		$ 59		$ 56


	Adjusted EBITDA		$ 73		$ 75		$ 71	-40


	of Sales		211		216		196


	GAAP Diluted EPS		$ (015)		$ 037		$ 025


	Adjusted Diluted EPS		$ 064		$ 083		$ 087	359	48


	Cash Flow from Operations			$ 38		$ 34

Page 25: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

3Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

BS Metrics

Debt

Payment

201720182019202020212022202331414898240964360

Cash Flows

4Q151Q162Q163Q1601109-7738000000000000421478999999999999

1Q162Q163Q164Q161109-773800000000000042147899999999999922068999999999996

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1396		$1376			$1395		$1375


Net Income		$13		$9			$86		$82


Earnings per Diluted Share		$042		$027			$275		$260


EBITDA		na		na			$295		$285


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		4Q16Actual		FY16Outlook


Revenue		$331		$348		$347		$360		$1375 - $1395


Adjusted


EBITDA		$65		$69		$75		$71		$285 - $295


Net Income		$13		$18		$26		$27		$82 - $86


Diluted EPS		$042		$056		$083		$087		$260 - $275


Net Synergies		$5		$9		$11		$11		$30 - $35

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

	4Q15		1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

WarrantyEampO		0		0		0		0		0

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		273	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 264	-303	13


	of Sales		247		176		172		209		191


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 9


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 208


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 030


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Page 26: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 4543 $ 7933 025 $(3746

1) $ (24907) (085)Adjustments

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Page 27: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

Income

NetIncome (Loss)

PerDilutedShare

As reported (GAAP) $ 1185 $ 5961 $ 019 $(1570

0) $ (7594) (029)Adjustments

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Page 28: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Page 29: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

2016January 1

2016December 30

2016January 1

EBITDA 55528 5592 202979 62445

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106

Page 30: 4Q16 Earnings Conference Call · 2Q16. 3Q16. 4Q16. $30 . $4 . $38 . $34 . 1Q16. 2Q16. 3Q16. Cash Flow From Operations Free Cash Flow ($ in millions) FY16. Debt Repayment Schedule

High Low High Low

Revenue $1430 $1390 $1430 $1390

4Q16 Slides --gt

Key Financial Results

Revenue

Cardio and Vascular

Adjusted EBITDA

4Q151Q162Q163Q164Q16789350000000000026537689270000000000077501699999999999670534999999999997

Cash Flows

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

Free Cash Flow

1Q162Q163Q164Q161109-773800000000000042147899999999999922069000000000003

1Q162Q163Q164Q1629858000000000001389599999999999993804500000000000233732999999999997

Debt

Payment

201720182019202020212022202331414898240964360

BS Metrics

Working Capital

1Q162Q163Q164Q1631789699999999993316610999999999993251580000000000233208699999999999

Guidance

Appendix --gt

OOE

Guidance-recon table

Debt Covenants

Contact Information

Integeririntegernet

wwwintegernet

(O) 2146184978

(M) 2144307208

Agenda
Opening Comments
Financial Results
Adjusted EBITDA
Working Capital
FY 2017 Outlook
Product Line Review
Cardio amp Vascular
Electrochem
Closing Comments
APPENDIX
Contact Information

Mechanics of Financial Covenant Calculations

	Financial Covenant Calculations(1)(2)

	Leverage Ratio (lt 625 4Q16)

	Leverage Ratio = Net Debt R12 Bank EBITDA


	Interest Coverage Ratio (gt 250 4Q16)

	Interest Coverage Ratio = R12 Bank EBITDA R12 Cash Interest Expense(3)

	Net Debt

	Net DEBT = Total Debt - Cash amp Cash Equivalents (not to exceed $50M)

	Bank EBITDA

	R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings(4)


	GAAP				Adjusted Comparable Basis

	High		Low			High		Low


Revenue		$1430		$1390			$1430		$1390


Earnings per Diluted Share		$150		$110			$310		$270


		Three Months Ended				Twelve Months Ended

		1116		123016			1116		123016		NOTES


	2014 Investments in Capacity and Capabilities		$52		$33			$230		$172		Portable Medical and Vascular product line transfers


	Orthopedic Facilities Optimization		$00		$01			$14		$07


	Legacy Lake Region Medical Consolidation and Optimization		$20		$12			$20		$86


	Acquisition and Integration Costs		$281		$52			$335		$283		Lake Region Medical and CCC Medical Devices


	Asset Dispositions Severance and Other		$17		$19			$66		$69		Nuvectra spin-off


	Comparable Basis Adjustments net(1)		$35		$00			$182		($11)


	TOTAL OOE		$405		$117			$847		$606


(1)		Details of Other Operating Expenses (OOE) provided on a comparable basis Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation (ldquoNuvectrardquo) prior to its spin-off on March 14 2016 Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical Historical pro forma information which was filed with the SEC on Form 8-K on February 29 2016 contains a reconciliation of 2015 comparable amounts to as reported amounts


	1Q16Actual		2Q16Actual		3Q16Actual		FY16Actual		FY17Outlook


Revenue		$331		$348		$347		$1386		$1390 - $1430


Adjusted Diluted EPS						$268		$270 - $310

	4Q15		1Q16		2Q16		3Q16		4Q16

Current Assets		$ 575		$ 534		$ 534		$ 525		$ 517

Current Liabilities		$ 214		$ 217		$ 217		$ 200		$ 185

Working Capital		$ 361		$ 318		$ 317		$ 325		$ 332

Current Ratio		27		25		25		26		28


	1Q16		2Q16		3Q16		4Q16


Free Cash Flow		$11		($8)		$21		$22


Days Sales Outstanding		50		50		50		52


Inventory		$252		$276		$262		$225


Inventory Turns		4		4		4		5


Capital Expenditures		$19		$12		$17		$12


Days Payables Outstanding		32		36		32		27


Sales		331058		348382		346567		359591

COGS		240244		252351		248658		266700

Accounts Recievables		183563		192121		191409		204626

Net Inventory		267380		276279		262232		225151

Accounts Payable		83306		99135		86290		77896

Debt Repayment Schedule

	2H16		2017		2018		2019		2020		2021		2022		2023				1Q16	2Q16	3Q16	4Q16	FY16

Payment		$ 15		$ 31		$ 41		$ 48		$ 98		$ 240		$ 964		$ 360			Reqd Debt Payments	73	73	73	73	290

										Addl Payments				50		100		150

											73		73		123		173		440

	4Q15		1Q16		2Q16		3Q16		4Q16			4Q15	1Q16		2Q16		3Q16		4Q16

Cash Flow from Operations		$ - 0		$ 30		$ 4		$ 38		$ 34		Free Cash Flow	$ - 0		$ 11		$ (8)		$ 21		$ 22

Free Cash Flow		$ - 0		$ 11		$ (8)		$ 21		$ 22		Capex		$ 19		$ 12		$ 17		$ 12

							Cash Flow from Operations		$ - 0		$ 30	$ 4	$ 38		$ 34

	4Q15		1Q16		2Q16		3Q16		4Q16

Adjusted EBITDA		$ 79		$ 65		$ 69		$ 75		$ 71

Revenue Details												4Q16					3Q16

		1Q15		2Q15		3Q15		4Q15		1Q16		2Q16		3Q16		4Q16		YOY		QOQ		YTD		YOY		QOQ		YTD

	Cardio and Vascular		$ 138		$ 145		$ 147		$ 133		$ 134		$ 144		$ 148		$ 142		74		-40		11		10		28		-08

	CardiacNeuromodulation		$ 99		$ 109		$ 94		$ 111		$ 96		$ 92		$ 96		$ 105		-54		95		-59		21		45		-62

	Advanced Surgical Orthopedics amp Portable Medical		$ 106		$ 109		$ 99		$ 105		$ 91		$ 104		$ 95		$ 102		-31		71		-62		-36		-87		-72

	Electrochem		$ 18		$ 17		$ 12		$ 13		$ 12		$ 10		$ 9		$ 11		-144		276		-299		-259		-97		-343

	Elimination of Interproduct line sales		$ (3)		$ (2)		$ (3)		$ (2)		$ (1)		$ (2)		$ (2)		$ (1)		-576		-379		-451		-488		-31		-415

		$ 358		$ 377		$ 348		$ 360		$ 331		$ 348		$ 347		$ 360		-05		38		-40		-05		-05		-53

Key Financial Results


		4Q15		3Q16		4Q16		FY15		FY16


	Sales		$ 360		$ 347		$ 360		$ 1443		$ 1386


	Gross Margin		215		283		258		264		272	(054)


	Operating Expenses		$ 89		$ 61		$ 62		$ 302		$ 270	-303	13


	of Sales		247		176		172		209		195


	GAAP Net Income		$ (47)		$ 11		$ 8		$ (39)		$ 6


	Adjusted Net Income		$ 28		$ 26		$ 27		$ 98		$ 84


	EBITDA		$ (7)		$ 59		$ 56		$ 161		$ 203


	Adjusted EBITDA		$ 79		$ 75		$ 71		$ 304		$ 280	-106


	of Sales		219		216		196		211		202


	GAAP Diluted EPS		$ (154)		$ 037		$ 025		$ (127)		$ 019


	Adjusted Diluted EPS		$ 087		$ 083		$ 087		$ 311		$ 268	00	48


	Cash Flow from Operations		--		$ 38		$ 34		--		$ 106